BeiGene completes redomestication to Switzerland, renamed BeOne Medicines Ltd.

BeOne Medicines Ltd.

Effective May 27, 2025, BeiGene continued from Cayman Islands to Switzerland, becoming BeOne Medicines Ltd.
New Swiss Articles and Organizational Regulations govern shareholder rights; ADSs continue on Nasdaq under ONC.
Executive employment agreements executed with CEO Oyler ($1.133M base), President Wu (RMB 6.0M), CFO Rosenberg ($660K), R&D head Wang (RMB 4.59M), and GC Lee ($654K).
Amended deposit agreement with Citibank and new indemnification agreements for directors and officers adopted.
Ordinary shares listed on HKEX (06160) and Shanghai STAR Market (688235) remain unchanged.

item 1.01 item 3.03 item 8.01 item 5.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BeOne Medicines Ltd.: Company continued from Cayman Islands to Switzerland; adopted Swiss Articles and Organizational Regulations, replacing the prior Seventh Amended and Restated Memorandum and Articles of Association (effective 2025-05-27).

Change: charter amendment
Effective: 2025-05-27

Exact text from the filing

The Swiss Articles and Organizational Regulations became effective as of May 27, 2025 in connection with the Continuation.

View on SEC.gov

Browse all governance changes →

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-25-052750

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.